[go: up one dir, main page]

IT1283102B1 - Composizione terapeutica per la somministrazione transdermica di un principio attivo estrogeno o progestinico o di loro miscele - Google Patents

Composizione terapeutica per la somministrazione transdermica di un principio attivo estrogeno o progestinico o di loro miscele

Info

Publication number
IT1283102B1
IT1283102B1 IT96MI001152A ITMI961152A IT1283102B1 IT 1283102 B1 IT1283102 B1 IT 1283102B1 IT 96MI001152 A IT96MI001152 A IT 96MI001152A IT MI961152 A ITMI961152 A IT MI961152A IT 1283102 B1 IT1283102 B1 IT 1283102B1
Authority
IT
Italy
Prior art keywords
progestinic
estrogenic
mixtures
active substance
therapeutic composition
Prior art date
Application number
IT96MI001152A
Other languages
English (en)
Inventor
Dario Carrara
Original Assignee
Permatec Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Permatec Nv filed Critical Permatec Nv
Publication of ITMI961152A0 publication Critical patent/ITMI961152A0/it
Priority to IT96MI001152A priority Critical patent/IT1283102B1/it
Priority to ES97108989T priority patent/ES2198516T3/es
Priority to DE69721377T priority patent/DE69721377T2/de
Priority to AT97108989T priority patent/ATE238801T1/de
Priority to DK97108989T priority patent/DK0811381T3/da
Priority to EP97108989A priority patent/EP0811381B1/en
Priority to JP18569597A priority patent/JP4293293B2/ja
Priority to NZ328021A priority patent/NZ328021A/en
Priority to US08/869,982 priority patent/US5891462A/en
Priority to CA002207144A priority patent/CA2207144C/en
Priority to AU24729/97A priority patent/AU712465B2/en
Priority to ZA9704981A priority patent/ZA974981B/xx
Priority to ARP970102497A priority patent/AR007530A1/es
Priority to TW086107807A priority patent/TW565462B/zh
Publication of ITMI961152A1 publication Critical patent/ITMI961152A1/it
Application granted granted Critical
Publication of IT1283102B1 publication Critical patent/IT1283102B1/it

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
IT96MI001152A 1996-06-06 1996-06-06 Composizione terapeutica per la somministrazione transdermica di un principio attivo estrogeno o progestinico o di loro miscele IT1283102B1 (it)

Priority Applications (14)

Application Number Priority Date Filing Date Title
IT96MI001152A IT1283102B1 (it) 1996-06-06 1996-06-06 Composizione terapeutica per la somministrazione transdermica di un principio attivo estrogeno o progestinico o di loro miscele
ES97108989T ES2198516T3 (es) 1996-06-06 1997-06-04 Una novedosa composicion para la administracion transdermica de un estrogeno, una progesterona o una mezcla de ambos.
DE69721377T DE69721377T2 (de) 1996-06-06 1997-06-04 Arzneimittel zur transdermalen Verabreichung von einem Östrogen oder Progestin oder einer Mischung davon
AT97108989T ATE238801T1 (de) 1996-06-06 1997-06-04 Arzneimittel zur transdermalen verabreichung von einem östrogen oder progestin oder einer mischung davon
DK97108989T DK0811381T3 (da) 1996-06-06 1997-06-04 Præparat til transdermal administration af en estrogen eller progestin eller en blanding deraf
EP97108989A EP0811381B1 (en) 1996-06-06 1997-06-04 A novel composition for transdermal administration of an estrogen, a progestin or a mixture thereof
JP18569597A JP4293293B2 (ja) 1996-06-06 1997-06-05 エストローゲン、プロゲスチンあるいはそれら混合物の新規なる経皮投与用組成物
NZ328021A NZ328021A (en) 1996-06-06 1997-06-05 Transdermal steroid gel medicament with permeation enhancer; contains c10-18 aliphatic alcohol and diethylene glycol monoalkyl ether as enhancer
US08/869,982 US5891462A (en) 1996-06-06 1997-06-05 Composition for transdermal administration of an estrogen
CA002207144A CA2207144C (en) 1996-06-06 1997-06-05 A novel composition for transdermal administration of an estrogen, a progestin or a mixture thereof
AU24729/97A AU712465B2 (en) 1996-06-06 1997-06-05 A novel composition for transdermal administration of an estrogen, a progestin or a mixture thereof
ZA9704981A ZA974981B (en) 1996-06-06 1997-06-05 A novel composition for transdermal administration of an estrogen, a progestin or a mixture thereof.
ARP970102497A AR007530A1 (es) 1996-06-06 1997-06-06 Gel para la administracion transdermica
TW086107807A TW565462B (en) 1996-06-06 1997-06-06 A novel composition for transdermal administration of estrogen, progestin or a mixture thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT96MI001152A IT1283102B1 (it) 1996-06-06 1996-06-06 Composizione terapeutica per la somministrazione transdermica di un principio attivo estrogeno o progestinico o di loro miscele

Publications (3)

Publication Number Publication Date
ITMI961152A0 ITMI961152A0 (it) 1996-06-06
ITMI961152A1 ITMI961152A1 (it) 1997-12-06
IT1283102B1 true IT1283102B1 (it) 1998-04-07

Family

ID=11374388

Family Applications (1)

Application Number Title Priority Date Filing Date
IT96MI001152A IT1283102B1 (it) 1996-06-06 1996-06-06 Composizione terapeutica per la somministrazione transdermica di un principio attivo estrogeno o progestinico o di loro miscele

Country Status (14)

Country Link
US (1) US5891462A (it)
EP (1) EP0811381B1 (it)
JP (1) JP4293293B2 (it)
AR (1) AR007530A1 (it)
AT (1) ATE238801T1 (it)
AU (1) AU712465B2 (it)
CA (1) CA2207144C (it)
DE (1) DE69721377T2 (it)
DK (1) DK0811381T3 (it)
ES (1) ES2198516T3 (it)
IT (1) IT1283102B1 (it)
NZ (1) NZ328021A (it)
TW (1) TW565462B (it)
ZA (1) ZA974981B (it)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19701949A1 (de) * 1997-01-13 1998-07-16 Jenapharm Gmbh Transdermales therapeutisches System
DE69840426D1 (de) * 1997-11-10 2009-02-12 Strakan Int Ltd Penetrationsfördernde und irritationsvermindernde Systeme mit Testosteron
JP3987655B2 (ja) * 1998-03-03 2007-10-10 エーザイ・アール・アンド・ディー・マネジメント株式会社 抗痴呆薬を含有した経皮適用製剤又は坐剤
FR2776191B1 (fr) * 1998-03-23 2002-05-31 Theramex Composition hormonale topique a effet systemique
GB9828480D0 (en) * 1998-12-24 1999-02-17 Dermatech Limited Transdermal drug delivery system
CA2381425A1 (en) 1999-08-24 2001-03-01 Cellgate, Inc. Enhancing drug delivery across and into epithelial tissues using oligo arginine moieties
DE10019171A1 (de) * 2000-04-07 2001-10-18 Schering Ag Zusammensetzungen zur Verwendung als Penetrationsverstärker in transdermalen Formulierungen für hoch lipophile Wirkstoffe
US7179483B2 (en) * 2000-04-26 2007-02-20 Watson Pharmaceuticals, Inc. Compositions and methods for transdermal oxybutynin therapy
US7029694B2 (en) * 2000-04-26 2006-04-18 Watson Laboratories, Inc. Compositions and methods for transdermal oxybutynin therapy
AU2001253782B2 (en) * 2000-04-26 2006-06-29 Allergan Sales, Llc Minimizing adverse experience associated with oxybutynin therapy
DE10025970C2 (de) * 2000-05-25 2002-04-25 Lohmann Therapie Syst Lts Estrogenhaltiges Pflaster mit einem Wirkstoffreservoir auf der Basis von Ethylcellulose und einem Ethylen-Vinylacetat-Vinylpyrrolidon-Copolymer und seine Verwendung
WO2002011768A1 (en) * 2000-08-03 2002-02-14 Antares Pharma Ipl Ag Novel composition for transdermal and/or transmucosal administration of active compounds that ensures adequate therapeutic levels
US20070225379A1 (en) * 2001-08-03 2007-09-27 Carrara Dario Norberto R Transdermal delivery of systemically active central nervous system drugs
US20040198706A1 (en) * 2003-03-11 2004-10-07 Carrara Dario Norberto R. Methods and formulations for transdermal or transmucosal application of active agents
US8980290B2 (en) 2000-08-03 2015-03-17 Antares Pharma Ipl Ag Transdermal compositions for anticholinergic agents
US7198801B2 (en) 2000-08-03 2007-04-03 Antares Pharma Ipl Ag Formulations for transdermal or transmucosal application
US20040092494A9 (en) * 2000-08-30 2004-05-13 Dudley Robert E. Method of increasing testosterone and related steroid concentrations in women
US20040002482A1 (en) * 2000-08-30 2004-01-01 Dudley Robert E. Androgen pharmaceutical composition and method for treating depression
US6503894B1 (en) 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
US20030027804A1 (en) * 2001-06-27 2003-02-06 Van Der Hoop Roland Gerritsen Therapeutic combinations for the treatment of hormone deficiencies
US20040062794A1 (en) * 2002-09-30 2004-04-01 Lee Shulman 17Beta- estradiol/levonorgestrel transdermal patch for hormone replacement therapy
FR2848112B1 (fr) * 2002-12-10 2007-02-16 Besins Int Belgique Composition pharmaceutique pour administration transdermique ou transmuqueuse comprenant au moins un progestatif et/ou au moins un oestrogene, son procede de preparation et ses utilisations
US7572780B2 (en) * 2003-01-21 2009-08-11 Dimera, Incorporated Method and kit for reducing the symptoms of peripheral vascular disease
FR2851470B1 (fr) * 2003-02-20 2007-11-16 Besins Int Belgique Composition pharmaceutique pour administration transdermique ou transmuqueuse
US20040253326A1 (en) * 2003-02-25 2004-12-16 Mesko Charles A. Composition for increasing levels of hormones and a method for preparation of said composition
CN1997357A (zh) * 2003-03-11 2007-07-11 安塔雷斯制药Ipl股份公司 透皮或透粘膜应用活性剂的用途和制剂
US7858607B2 (en) * 2003-03-14 2010-12-28 Mamchur Stephen A System for use by compounding pharmacists to produce hormone replacement medicine customized for each consumer
US7879357B2 (en) 2003-04-28 2011-02-01 Bayer Schering Pharma Ag Pharmaceutical composition in the form of a hydrogel for transdermal administration of active ingredients
JO2492B1 (en) 2003-04-28 2009-10-05 شيرينج ايه جي A pharmaceutical formula in the form of aqueous gel for the skin use of its active ingredients
BRPI0414551B8 (pt) 2003-10-10 2021-05-25 Antares Pharma Ipl Ag formulação farmacêutica transdérmica ou transmucosa e método de protelação ou inibição da cristalização de um agente ativo
US7387788B1 (en) 2003-10-10 2008-06-17 Antares Pharma Ipl Ag Pharmaceutical compositions of nicotine and methods of use thereof
US7780973B2 (en) * 2003-12-15 2010-08-24 Ethicon Endo-Surgery, Inc. Method and device for minimally invasive implantation of biomaterial
US7425340B2 (en) 2004-05-07 2008-09-16 Antares Pharma Ipl Ag Permeation enhancing compositions for anticholinergic agents
JP2007045808A (ja) * 2005-01-07 2007-02-22 Rohto Pharmaceut Co Ltd 皮膚外用剤
JP4969050B2 (ja) * 2005-01-07 2012-07-04 ロート製薬株式会社 皮膚外用剤
US20070088012A1 (en) * 2005-04-08 2007-04-19 Woun Seo Method of treating or preventing type-2 diabetes
US8067399B2 (en) 2005-05-27 2011-11-29 Antares Pharma Ipl Ag Method and apparatus for transdermal or transmucosal application of testosterone
KR100699582B1 (ko) 2005-07-11 2007-03-23 삼성전기주식회사 출력 버퍼회로
DK2450041T3 (en) 2005-10-12 2018-11-19 Unimed Pharmaceuticals Llc Enhanced testosterone gel for use in the treatment of hypogonadism
US20070254036A1 (en) * 2006-04-13 2007-11-01 Besins Healthcare Sa Treatment of menopause associated symptoms
CN101426475A (zh) 2006-04-21 2009-05-06 安塔雷斯制药Ipl股份公司 使用用于经皮或经粘膜应用的制剂治疗热潮红的方法
WO2008067991A2 (en) * 2006-12-08 2008-06-12 Antares Pharma Ipl Ag Skin-friendly drug complexes for transdermal administration
JP4825305B2 (ja) * 2007-09-20 2011-11-30 株式会社 資生堂 経皮吸収製剤
WO2010008600A1 (en) * 2008-07-16 2010-01-21 Dermworx Incorporated Topical drug delivery system
US10080760B2 (en) 2009-10-27 2018-09-25 Besins Healthcare Luxembourg Sarl Transdermal pharmaceutical compositions comprising active agents
FR2954980B1 (fr) 2010-01-04 2012-02-10 Guillemot Corp Joystick a ressorts de compensation, procede de fabrication et manette correspondants.
US20130045958A1 (en) 2011-05-13 2013-02-21 Trimel Pharmaceuticals Corporation Intranasal 0.15% and 0.24% testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder
US20130040923A1 (en) 2011-05-13 2013-02-14 Trimel Pharmaceuticals Corporation Intranasal lower dosage strength testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder
US9757388B2 (en) 2011-05-13 2017-09-12 Acerus Pharmaceuticals Srl Intranasal methods of treating women for anorgasmia with 0.6% and 0.72% testosterone gels
JP5820207B2 (ja) 2011-09-13 2015-11-24 日東電工株式会社 経皮吸収促進用組成物および貼付製剤
JP5820206B2 (ja) * 2011-09-13 2015-11-24 日東電工株式会社 経皮吸収促進用組成物および貼付製剤
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
CA2856520C (en) 2011-11-23 2021-04-06 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11744838B2 (en) 2013-03-15 2023-09-05 Acerus Biopharma Inc. Methods of treating hypogonadism with transnasal testosterone bio-adhesive gel formulations in male with allergic rhinitis, and methods for preventing an allergic rhinitis event
AU2015264003A1 (en) 2014-05-22 2016-11-17 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
MX2016013693A (es) 2014-07-29 2017-10-31 Therapeuticsmd Inc Crema transdermica.
US10264664B1 (en) 2015-06-04 2019-04-16 Vlt, Inc. Method of electrically interconnecting circuit assemblies
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10493049B2 (en) 2016-02-10 2019-12-03 Niracle LLC Applicator-based transdermal drug delivery system for administration of drugs in combination with topical formulations
JP2019513709A (ja) 2016-04-01 2019-05-30 セラピューティックスエムディー インコーポレーテッドＴｈｅｒａｐｅｕｔｉｃｓｍｄ， Ｉｎｃ． ステロイドホルモン薬学的組成物
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
US10556717B2 (en) 2017-03-10 2020-02-11 E-Pac Packaging Services Co. Ltd. Packaging assembly comprising a tightening portion, a box portion, a flexible strip and a pair of securing members
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations
EP4308088B1 (en) 2021-11-08 2025-03-12 Weiyong Li Transdermal drug delivery system for delivering a drug to a patient

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4315925A (en) * 1980-05-30 1982-02-16 University Of Kentucky Research Foundation Method of administering natural female sex hormones
FR2518879A1 (fr) * 1981-12-30 1983-07-01 Besins Jean Medicament a base d'oestradiol pour le traitement de la pathologie menopausique
US5145682A (en) * 1986-05-30 1992-09-08 Rutgers, The State University Of New Jersey Transdermal absorption dosage unit for postmenopausal syndrome treatment and process for administration
US5023084A (en) * 1986-12-29 1991-06-11 Rutgers, The State University Of New Jersey Transdermal estrogen/progestin dosage unit, system and process
US4788062A (en) * 1987-02-26 1988-11-29 Alza Corporation Transdermal administration of progesterone, estradiol esters, and mixtures thereof
CH674618A5 (it) * 1987-04-02 1990-06-29 Ciba Geigy Ag
US4942158A (en) * 1988-10-13 1990-07-17 Eastman Kodak Transdermal steroid penetrant compositions and methods utilizing isopropanol and isobutanol
EP0370220B1 (de) * 1988-10-27 1996-01-10 Schering Aktiengesellschaft Mittel zur transdermalen Applikation enthaltend Gestoden
US4973468A (en) * 1989-03-22 1990-11-27 Cygnus Research Corporation Skin permeation enhancer compositions
DE69010076T2 (de) * 1989-05-25 1994-12-08 Takeda Chemical Industries Ltd Transdermales therapeutisches Mittel.
US4956171A (en) * 1989-07-21 1990-09-11 Paco Pharmaceutical Services, Inc. Transdermal drug delivery using a dual permeation enhancer and method of performing the same
SE8904296D0 (sv) * 1989-12-21 1989-12-21 Pharmacia Ab Transdermal system
JP3046346B2 (ja) * 1990-03-12 2000-05-29 昭和電工株式会社 外用剤基剤又は補助剤とそれを含有する人又は動物の外用剤
US5453279A (en) * 1992-04-21 1995-09-26 Tbs Laboratories, Inc. Enhancing transdermal absorption compositions; transdermal dosage form; and process

Also Published As

Publication number Publication date
NZ328021A (en) 1997-11-24
CA2207144C (en) 2008-07-29
AU2472997A (en) 1997-12-11
DK0811381T3 (da) 2003-08-25
JP4293293B2 (ja) 2009-07-08
DE69721377D1 (de) 2003-06-05
CA2207144A1 (en) 1997-12-06
JPH1072351A (ja) 1998-03-17
EP0811381B1 (en) 2003-05-02
US5891462A (en) 1999-04-06
AR007530A1 (es) 1999-11-10
AU712465B2 (en) 1999-11-04
EP0811381A1 (en) 1997-12-10
ITMI961152A0 (it) 1996-06-06
ES2198516T3 (es) 2004-02-01
TW565462B (en) 2003-12-11
ZA974981B (en) 1998-01-23
DE69721377T2 (de) 2004-04-01
ATE238801T1 (de) 2003-05-15
ITMI961152A1 (it) 1997-12-06

Similar Documents

Publication Publication Date Title
IT1283102B1 (it) Composizione terapeutica per la somministrazione transdermica di un principio attivo estrogeno o progestinico o di loro miscele
FI971776L (fi) Yhdisteet ja koostumukset aktiivisten aineiden antamiseksi
EE9700241A (et) Farmatseutiline kompositsioon transdermaalseks manustamiseks
FI972542L (fi) Transdermaalijärjestelmä useamman aktiivisen aineen samanaikaista antamista varten
NO980126D0 (no) Plaster-formulering for perkantal administrering av fenantyl
HUP0000558A3 (en) Use of active d vitamin analogues for producing pharmaceutical composition for the treatment of prostatic diseases
DK0797991T3 (da) Lægemiddelformulering med forhalet frigivelse
FI973828A0 (fi) Yhdisteitä ja koostumuksia aktiivisten aineiden annostelemiseksi
NO20006630D0 (no) Farmasöytisk sammensetning for behandlingen av diabetes
EE04390B1 (et) Paikne preparaat dermatoloogiliste seisundite raviks
ID22878A (id) Komposisi aktif secara terapi
FI980822A0 (fi) Farmaseuttinen koostumus vaikuttavan aineen iho- tai limakalvopintaan tai iho- tai limakalvopinnan läpi
FI973452L (fi) Nauhoitettu annosmuoto aktiivisen aineen pidennettyyn jakamiseen
FI953533L (fi) Transdermaalinen terapeuttinen järjestelmä, jossa on galantamiinia vaikuttavana aineena
DE69807634D1 (de) Medizinische einrichtung zur verabreichung von therapeutischen wirkstoffen
ID19755A (id) Komposisi untuk pemberian transdermal obat-obat steroid
FI954990L (fi) Aktiiviainetta sisältävä transdermaalinen valmiste
EE04238B1 (et) Asendatud 1,2,3,4-tetrahüdronaftaleeni derivaadid, meetod selle valmistamiseks, nimetatud terapeutilise toimega aineid sisaldavad ravimkoostised ja nimetatud aktiivsete ühendite kasutamine teraapias
DK0941075T3 (da) Smagsmaskerende farmaceutisk doseringsform med hurtig frigivelse
GB2311940B (en) Pharmaceutical compositions for the treatment of rhinitis
ATE210429T1 (de) Therapie mittels gleichförmiger arzneistoffverabreichung
ID24259A (id) Formulasi obat yang memiliki pelepasan senyawa aktif terkontrol
FI955260A7 (fi) Transdermaalisia terapeuttisia systeemejä serotoniiniagonistien antami sta varten
ID29966A (id) Sulfoniloksazolamina-sulfoniloksazolamina sebagai senyawa-senyawa aktif terapi
NO890155L (no) Fremgangsmaate for fremstilling av terapeutisk aktive indolpiperidin-forbindelser.

Legal Events

Date Code Title Description
0001 Granted